赛诺菲喜保宁在国内有售吗？

(Vigabatrin), developed by the French company Sanofi, was approved for marketing in the UK in 1989, and was approved by the US Food and Drug Administration in 2009 for the treatment of infantile spasms and refractory focal epilepsy, making it one of the first-choice drugs for the treatment of infantile spasms, especially for patients with tuberous sclerosis. Is Sanofi Vigabatrin available in the country?

Sanofi Vigabatrin has not yet been approved for marketing in China. It is neither produced by manufacturers nor sold by merchants. Most patients can only find someone to purchase it on their behalf. Many people have been deceived and bought fake and inferior drugs, which has worsened their condition. If patients need Sanofi Vigabatrin listed overseas, they can contact domestic legal and professional overseas medical service organizations (such as Medical Companion Travel) to obtain it.

Vigabatrin is an analog of gamma-aminobutyric acid (GABA). It can specifically bind to GABA aminotransferase and irreversibly, leading to an increase in GABA concentration in the brain, thus exerting anti-epileptic effects. Vigabatrin is used as adjunctive therapy in patients who are refractory to other antiepileptic drugs, especially those with partial seizures (mainly used to control complex partial seizures). Vigabatrin may also be used in infants with West syndrome (infantile spasms), which is generally unresponsive to conventional antiepileptic drugs. As an auxiliary treatment drug, it can achieve better curative effect. When used alone, it is effective in the treatment of newly diagnosed patients.

Recommended related hot articles: /newsDetail/95638.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.